CYT003-QbG10 for Treatment of Allergic Asthma Bronchial

A Double-blind, Placebo-controlled Study to Assess Pharmacodynamic and Clinical Efficacy of CYT003-QbG10 in Patients With Persistent Allergic Asthma Bronchial

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00890734

Enrollment

Registered

2009-04-30

Start date

2009-04-30

Completion date

2010-11-30

Last updated

2012-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Bronchial Asthma

Brief summary

The purpose of the study is to test whether treatment with CYT003-QbG10 can improve asthma symptoms in patients with allergic bronchial asthma. The active treatment will be compared against placebo.

Interventions

DRUGCYT003-QbG10

subcutaneous injection

DRUGPlacebo

subcutaneous injection

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Persistent allergic asthma bronchial requiring long-term treatment with inhaled corticosteroids * Further criteria as defined in the study protocol

Exclusion criteria

* Use of oral corticosteroids within past 3 months * Hospitalization for asthma exacerbation within past 6 months * Uncontrolled asthma * Contraindication to any study test or procedure * Further criteria as defined in the study protocol

Design outcomes

Primary

Measure	Time frame
Markers for inflammation and asthma	1-3 months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026